The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. by Lawlor, Debbie A et al.
Lawlor, DA; Day, IN; Gaunt, TR; Hinks, LJ; Briggs, PJ; Kiessling,
M; Timpson, N; Smith, GD; Ebrahim, S (2004) The association of
the PON1 Q192R polymorphism with coronary heart disease: find-
ings from the British Women’s Heart and Health cohort study and a
meta-analysis. BMC Genet, 5 (1). p. 17. ISSN 1471-2156
Downloaded from: http://researchonline.lshtm.ac.uk/12730/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
BioMed Central
Page 1 of 12
(page number not for citation purposes)
BMC Genetics
Open AccessResearch article
The association of the PON1 Q192R polymorphism with coronary 
heart disease: findings from the British Women's Heart and Health 
cohort study and a meta-analysis
Debbie A Lawlor*1, Ian NM Day2, Tom R Gaunt2, Lesley J Hinks2, 
Patricia J Briggs2, Matthew Kiessling2, Nick Timpson1, George Davey Smith1 
and Shah Ebrahim1
Address: 1Department of Social Medicine, University of Bristol, Bristol, UK and 2Human Genetics Division, School of Medicine, University of 
Southampton School of Medicine, Southampton, UK
Email: Debbie A Lawlor* - d.a.lawlor@bristol.ac.uk; Ian NM Day - imnd@soton.ac.uk; Tom R Gaunt - trg1@soton.ac.uk; 
Lesley J Hinks - ijh3@soton.ac.uk; Patricia J Briggs - pjb1@soton.ac.uk; Matthew Kiessling - mgk@soton.ac.uk; 
Nick Timpson - n.timpson@bristol.ac.uk; George Davey Smith - zetkin@bristol.ac.uk; Shah Ebrahim - shah.ebrahim@bristol.ac.uk
* Corresponding author    
Abstract
Background: There have been inconsistent results from case-control studies assessing the
association of the PON1 Q192R polymorphism with coronary heart disease (CHD). Most studies
have included predominantly men and the association in women is unclear. Since lipid levels vary
between the sexes the antioxidant effect of PON1 and any genes associated with it may also vary
by sex. We have examined the association of the PON1 Q192R polymorphism with CHD in a large
cohort of British women and combined the results from our cohort study with those from all other
published studies.
Results: The distribution of genotypes was the same among women with CHD and those without
disease. The odds ratio (95% confidence interval) of having CHD comparing those with either the
QR or RR genotype to those with QQ genotype (dominant model of association) was 1.03 (0.89,
1.21) and the per allele odds ratio was 0.98 (0.95, 1.01). In a meta-analysis of this and 38 other
published studies (10,738 cases and 17,068 controls) the pooled odds ratio for the dominant effect
was 1.14 (1.08, 1.20) and for the per allele effect was 1.10 (1.06, 1.13). There was evidence of small
study bias in the meta-analyses and the dominant effect among those studies with 500 or more
cases was 1.05 (0.96, 1.15). Ethnicity and reporting of whether the genotyping was done blind to
the participants clinical status also contributed to heterogeneity between studies, but there was no
difference in effect between studies with 50% or more women compared to those with fewer
women and no difference between studies of healthy populations compared to those at high risk
(with diabetes, renal disease of familial hypercholesterolaemia).
Conclusion: There is no robust evidence that the PON1 Q192R polymorphism is associated with
CHD risk in Caucasian women or men.
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Background
Coronary heart disease (CHD) has a multifactorial aetiol-
ogy involving physiological, environmental and genetic
factors, leading to increased susceptibility [1]. High-den-
sity lipoprotein cholesterol (HDLc) is protective against
CHD but the mechanisms underlying this protective effect
are not fully understood. One plausible mechanism is
related to the antioxidant properties of HDLc [2]. HDLc
appears to protect against oxidation of low-density lipo-
protein cholesterol (LDLc) and oxidation of LDLc is
important in the initiation and progression of atheroscle-
rosis [3,4]. The antioxidant effect of HDLc is determined
by its enzymes, in particular paraoxonase 1 (PON1),
which catalyzes the hydrolysis of lipid peroxides, as well
as being a potent hydroliser of a number of other sub-
strates, including the active metabolites of organophos-
phates [5-8]. These findings have led to the suggestion
that PON1 activity has a role in susceptibility to athero-
sclerotic disease [5,9]. A strong association between a pol-
ymorphism in the PON1 gene (in which an amino acid
substitution (glutamine (Q) for arginine (R) at position
192 gives rise to 2 alloenzymes) and PON1 activity has
been found [10,11]. The effect of the polymorphism var-
ies depending upon the substrate, for example the R
alloenzyme is associated with faster hydrolysis of
paraoxon but slower hydrolysis of diazinonoxon [10,11].
It has been shown that the R alloenzyme confers least abil-
ity of HDLc to prevent oxidation of LDLc, mediated
through the level of PON1 enzyme activity [12].
Several case-control studies have assessed the association
of the PON1 Q192R polymorphism with CHD, and a
recent review and meta-analysis of these studies found a
weak overall effect but with evidence of small study bias,
such that there was no effect when results were pooled
only for studies including 500 or more cases [13]. In the
majority of studies to date 75% or more of the partici-
pants have been male (see Additional file 1) and the effect
of the polymorphism in women is unclear. Since lipid lev-
els vary by sex, with adult women having higher levels of
HDLc than men, it is plausible that any effect of the poly-
morphism and of PON1 activity will vary by sex.
The aim of this study is to assess the association of the
PON1 Q192R polymorphism with CHD in a large cohort
study of women only, and to update the previous meta-
analysis in this area. We have identified an additional
three studies that were not included in the previous meta-
analysis which together with our own study add 865 cases
and 5452 controls to that analysis.
Results
The British Women's Heart and Health Study
Of the 4,278 participants who gave consent for genetic
testing 15 (5 Afro-Caribbean, 8 South Asian and 2 other)
were defined by the examining nurse as being non-Cauca-
sian and have been excluded from further analysis. Of the
remaining 4,263 women 3,545 (83%) had DNA available
for genotyping and for 3,266 (92%) of these women gen-
otypic data were available. There was no difference in
mean age (68.8 (5.5) versus 69.0 (5.6) years, p = 0.23)
and no difference in the prevalence of CHD (14.7% [480
cases out of 3266] of those with genotypic data versus
15.4% [155 cases out of 1005] of those without genotypic
data, p = 0.36) between those with and without genotypic
data. The allele frequencies were in Hardy Weinberg equi-
librium among women with no evidence of CHD (p =
0.14) and among those with CHD (p = 0.42). Of the
3,266 women with genotypic data 480 (14.7%) had
CHD.
The association of PON1 Q192R polymorphism with 
coronary heart disease in the British Women's Heart and 
Health Study
Table 1 shows the characteristics of the study population
by genotype. Genotype was not associated with CHD,
obesity, insulin resistance, diabetes, dyslipidaemia, socio-
economic position or smoking. Systolic blood pressure
appeared higher among those with the RR genotype com-
pared to either those with QQ or QR genotypes, but this
may be a chance finding since, unlike lipid levels and
CHD which would be hypothesised to be associated with
this polymorphism, we had no strong a priori hypothesis
of an association with blood pressure and would therefore
only be convinced that the result was not due to chance by
a very small p value. The genotype frequencies for those
with CHD did not differ from those not experiencing such
an event (p = 0.2, see final row of Additional file 1).
Table 2 shows the results of the logistic regression analyses
of the association of the PON1 Q192R genotype with
myocardial infarction only, angina and CHD, with differ-
ent genetic models (dominant, recessive and per allele
effect). There was no evidence from any of these that
PON1 Q192R genotype was associated with CHD. The
odds ratio (95% confidence interval) of having CHD
comparing those with either the QR or RR genotype to
those with QQ genotype (dominant model of associa-
tion) was 1.03 (0.89, 1.21) and the per allele odds ratio
was 0.98 (0.95, 1.01). Adjustment for potential mediating
or confounding factors (as listed in the first column of
table 1) did not alter any of the associations presented in
Table 2.
Systematic review and meta-analysis of all previously 
published studies
Table summarising all previously published studies (see Additional file 
1)
A table summarising all previously published studies is
located in word format in additional file 1. The file is
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named 'summaryT' and the title of the table is 'Summary
of studies examining the association between PON1
Q192R polymorphism and coronary heart disease'. The
table lists the study design, population details, numbers
of cases and controls with each allele and information
about study quality.
We identified 38 studies that assessed the association
between PON1 Q192R genotype and CHD [14-51].
Together with our own, British Women's Heart and
Health study, these studies provide data on 10,738 CHD
cases and 17,068 controls. Compared to a recently pub-
lished meta-analysis[13] we included three additional
studies [39,40,50]. One of these studies [39] was identi-
fied by the previous reviewers but excluded because it was
Table 1: Characteristics of study participants by genotype for PONS1 Q192R polymorphism (N = 3,266)
Variable Means or [N] % (95% CI) by genotype P heterogeneitya
QQ N = 1669 QR N = 1326 RR N = 271
Dichotomous variables
Myocardial infarction (MI) [53] 3.2 (2.4, 4.3) [46] 3.5 (2.6, 4.8) [12] 4.4 (2.3, 7.6) 0.51
Angina (but no history of MI) [186] 11.1 (9.7, 12.8) [165] 12.4 (10.7, 14.3) [18] 6.6 (4.0, 10.3) 0.13
Any CHD (MI or angina) [239] 14.3 (12.7, 16.1) [211] 15.9 (14.1, 18.0) [30] 11.1 (7.6, 15.4) 0.14
Diabetes at baseline [75] 4.5 (3.6, 5.6) [70] 5.3 (4.3, 6.7) [12] 4.4 (2.5, 7.6) 0.61
Current smoker [189] 11.3 (9.9, 12.9) [163] 12.3 (10.6, 14.1) [22] 8.1 (5.4, 11.9) 0.12
Ever smoker [746] 44.6 (42.2, 47.0) [596] 44.9 (42.3, 47.6) [116] 42.9 (37.1, 48.8) 0.82
Adult manual social class [964] 57.8 (55.4, 60.2) [725] 54.7 (52.0, 57.3) [157] 57.9 (51.9, 63.6) 0.20
Childhood manual social class [1334] 79.9 (77.9, 81.8) [1075] 81.1 (78.9, 83.1) [219] 81.0 (75.9, 85.2) 0.72
On statin [126] 7.5 (6.4, 8.9) [95] 6.9 (5.6, 8.3) [25] 9.2 (6.3, 13.2) 0.41
Continuous variables
Age 68.8 (68.6, 69.1) 68.8 (68.5, 69.1) 68.9 (68.3, 68.3) 0.91
HOMAc 1.64 (1.59, 1.70) 1.72 (1.66, 1.79) 1.69 (1.56, 1.82) 0.15
Total cholesterol 6.64 (6.58, 6.70) 6.65 (6.58, 6.72) 6.61 (6.46, 6.75) 0.85
HDLc 1.65 (1.63, 1.67) 1.65 (1.63, 1.68) 1.70 (1.65, 1.76) 0.18
LDLc 4.15 (4.09, 4.20) 4.15 (4.09, 4.21) 4.02 (3.89, 4.16) 0.21
Triglyceridesc 1.67 (1.64, 1.71) 1.69 (1.65, 1.73) 1.71 (1.62, 1.81) 0.73
Systolic BP 148.3 (147.1, 149.5) 146.0 (144.6, 147.3) 150.4 (147.4, 153.4) 0.006
Diastolic BP 79.9 (79.3, 80.4) 78.9 (78.3, 79.6) 80.3 (78.9, 81.8) 0.05
BMI 27.6 (27.3, 27.8) 27.6 (27.4, 27.9) 27.6 (27.0, 28.2) 0.96
WHR 0.817 (0.814, 0.821) 0.821 (0.817, 0.824) 0.826 (0.818, 0.834) 0.11
a χ2 for dichotomous variables and ANOVA for continuous variables bOccurrence of a new CHD event (death from CHD, new diagnosis of MI / 
angina, new CABG or angioplasty). All other characteristics are from baseline measures cGeometric means
Table 2: Results of logistic regression analysis for the association of PON1 Q192R genotype with coronary heart disease (CHD) in the 
British Women's Heart and Health study N = 3,266
Genotype OR (95% CI) for myocardial infarction [N = 111] OR (95% CI) for angina [N = 369] OR (95% CI) for any CHD [N = 480]
Dominant model
QQ 1 1 1
QR or RR 1.13 (0.76, 1.70) p = 0.49 1.04 (0.84, 1.27) p = 0.64 1.03 (0.89, 1.21) p = 0.62
Recessive model
QQ or QR 1 1 1
RR 1.42 (0.76, 2.64) p = 0.26 0.67 (0.44, 1.01) p = 0.06 0.79 (0.59, 1.05) p = 0.11
Per allele
QQ 1 1 1
QR 1.09 (0.72, 1.67) 1.12 (0.91, 1.39) 1.09 (0.92, 1.28)
RR 1.45 (0.76, 2.78) 0.70 (0.46, 1.08) 0.82 (0.60, 1.11)
Per allele 1.04 (0.98, 1.10) p = 0.24 0.98 (0.93, 1.02) p = 0.11 0.98 (0.95, 1.01) p = 0.16
OR: odds ratio; CI: confidence interval; CHD: coronary heart disease
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in a population with familial hypercholesterolaemia. It
has been suggested that the PON1 Q192R polymorphism
has greater effects in populations at greater risk of CHD
[5,9] and therefore we decided a priori not to exclude stud-
ies of high risk populations but to determine whether
there was heterogeneity between these studies and those
on healthy populations. The previous review did include
studies in diabetic populations and one in patients who
had undergone renal transplants [13]. A second study [40]
was published within the time frame of the search of the
previous review but was in an obscure Chinese journal
which we had difficulty locating. The third study [50], a
large prospective study, was published prior to publica-
tion of the recent review and meta-analysis but was later
than the date at which those reviewers completed their
search. Combining our study with these three studies pro-
vides an additional 865 cases and 5452 controls com-
pared to the previous meta-analysis [13].
Table 3 presents the results of the meta-analyses and Fig-
ure 1 shows the meta-analysis of the odds ratio for any
CHD comparing either QR or RR genotype to QQ geno-
type (dominant effect). These results suggest a weak asso-
ciation between the R allele and increased CHD risk. The
pooled odds ratio for the dominant effect was 1.14 (1.08,
1.20) and for the per allele effect was 1.10 (1.06, 1.13).
However, there was marked heterogeneity between stud-
ies in most of these meta-analyses and there was evidence
of small study bias (both Egger and Begg's tests produced
p-values between 0.003 and 0.04 for the different
models).
Study size, ethnicity and whether the study reported
blinding of the genotyping were all independently associ-
ated with heterogeneity between studies (all p-values <
0.04), though heterogeneity tended to remain even within
these sub-groups. Figure 2 shows the differences in effect
size according to study size, ethnicity, and blinding of the
genotyping. The pooled effect from four studies with 500
or more cases suggested no association between genotype
and CHD: the dominant effect (shown in Figure 2) was
1.05 (0.96, 1.15) and the per allele effect was 1.04 (0.98,
1.14). There appeared to be greater detrimental effect of
the R allele among East-Asian and other non-Caucasian
populations, but these pooled estimates were imprecise
due to small numbers of small sized studies in these sub-
groups. Studies that did not provide information on
whether the genotyping was undertaken blind to the clin-
ical status of study participants tended to show stronger
effects. Lack of provision of this information may be a
general marker of poor study quality, with meta-analyses
in other areas suggesting that poor study quality tends to
result in exaggerated effects [52].
There was no evidence of differences in the effect of the
polymorphism between studies that included 50% or
more women and those in which fewer than 50% of the
participants were women: pooled odds ratio for the effect
of QR or RR genotype versus QQ genotype among studies
with 50% or more women was 1.13 (0.99, 1.24) and that
among studies with fewer than 50% women was 1.15
(1.08, 1.22). There was no difference in effect between
studies in healthy compared to diseased populations (p =
0.16). Further, the method of diagnosis of CHD (angio-
graphic diagnosis or diagnosis of MI based on at least two
of three of classical chest pain symptoms, cardiac enzyme
changes or ECG changes versus softer diagnoses of angina
without angiography or self-report) did not explain any
heterogeneity between studies (p = 0.87).
Table 3: Results of meta-analysis of 39 studies (N = 10,738 cases and 17,068 controls) of the association of PON1 Q192R genotype with 
coronary heart disease (CHD)
OR (95% CI) for myocardial 
infarction
OR (95% CI) for angina OR (95% CI) for any CHD
Dominant model
Fixed effect 1.10 (1.03, 1.18) 1.18 (1.09, 1.27) 1.14 (1.08, 1.20)
Random effect 1.12 (1.01, 1.23) 1.26 (1.08, 1.46) 1.19 (1.08, 1.30)
p heterogeneity 0.08 < 0.001 < 0.001
Recessive model
Fixed effect 1.14 (1.01, 1.28) 1.12 (1.00, 1.25) 1.13 (1.04, 1.22)
Random effect 1.14 (1.01, 1.28) 1.14 (0.99, 1.33) 1.13 (1.02, 1.24)
p heterogeneity 0.72 0.01 0.08
Per allele
Fixed effect 1.06 (1.01, 1.12) 1.13 (1.06, 1.20) 1.10 (1.06, 1.13)
Random effect 1.07 (1.01, 1.13) 1.15 (1.05, 1.24) 1.11 (1.06, 1.15)
p heterogeneity 0.12 < 0.001 < 0.001
OR: odds ratio; CI: confidence interval; CHD: coronary heart disease
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Discussion
In our cohort study of women we found no evidence of an
association between PON1 Q192R polymorphism and
CHD. In a meta-analysis of this study together with 38
previously published studies there was a weak association
between the R allele and increased CHD risk. However,
there was evidence of small study bias and the pooled esti-
mate from studies including 500 or more cases suggested
no association between the polymorphism and CHD. The
overall effect did not differ between studies containing
predominantly men and those with a predominance of
women. Overall we would conclude that there is no
strong evidence that the PON1 Q192R polymorphism is
associated with CHD risk in either Caucasian men or
women. Our results cannot rule out an important effect of
this polymorphism in some non-Caucasian populations.
However, there is insufficient evidence in these subgroups
to make precise estimates of the effect currently in these
populations. Previous studies reporting an association
demonstrate the particular problems of false positive
genetic associations due to chance findings and small
study bias [53].
It has been suggested that the polymorphism has a greater
effect among individuals at high risk of heart disease, such
as diabetics or those with familial hypercholesteroloae-
mia [5,7], therefore heterogeneity between studies may be
due to some consisting of high risk participants whereas
others are in healthy populations. However, our meta-
analysis suggested that effects were similar in those at high
risk (individuals with diabetes, familial hypercholestero-
laemia or renal disease) and healthy individuals.
Meta-analysis of association of PON1 Q192R polymorphism with coronary heart disease (dominant model: QR or RR genotype versus QQ genotype)Figure 1
Meta-analysis of association of PON1 Q192R polymorphism with coronary heart disease (dominant model: QR or RR genotype 
versus QQ genotype). Based on a total of 10738 cases and 17068 controls from 39 studies.
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Can the principles of Mendelian randomisation be used to 
deduce the effects of PON1 activity on CHD from the 
PON1 genotype-CHD association results?
It has been proposed that the principles of Mendelian ran-
domisation can be used to assess unconfounded associa-
tions between phenotypes and disease outcomes. [54,55]
The basic idea uses the fact that the random assortment of
genes from parents to offspring that occurs during gamete
formation and conception results in genotype being inde-
pendent of socio-environmental factors. Thus a genotype-
disease association provides support for a causal associa-
tion between a phenotype (that is functionally related to
the genotype) and disease. Although it has been suggested
that the Q192R polymorphism accounts for only a small
part of the 40-fold individual variation in PON1 activity
[9], if, as is proposed the R allele is functionally related to
PON1 activity resulting in a reduced ability to prevent
oxidation of LDLc, individuals with one or two R alleles
will, on average, have had lower exposure to PON1 anti-
oxidant effects during their lives than those who are
homozygous for the Q allele, permitting an assessment of
the effect of this lower exposure on risk of CHD. The many
other environmental and genetic factors determining
PON1 activity, which would confound a comparison
between PON1 enzyme activity and CHD risk, should not
confound the PON1 genotype-CHD association owing to
the random assortment of genes from parents to offspring
that occurs during gamete formation and conception, the
principle of Mendelian randomisation [54,55]. This is
demonstrated in Table 1, where the major physiological
and environmental risk factors for CHD are similarly dis-
tributed. In addition to avoidance of any confounding
effect, the genotype-CHD association avoids the
possibility that PON1 antioxidant activity might be
caused by the onset of CHD, that is reverse causality [55].
However, the use of Mendelian randomisation in this
Pooled estimates of the association of PON1 Q192R polymorphism with coronary heart disease (dominant model: QR or RR genotyp  versus QQ g notype) by study characteristicsFigure 2
Pooled estimates of the association of PON1 Q192R polymorphism with coronary heart disease (dominant model: QR or RR 
genotype versus QQ genotype) by study characteristics
OR (95% CI) of CHD
0.5 1.0 2.0
Study size –
number cases
Ethnicity
Genotyping done 
blind to clinical 
status
> 500
200-499
< 200
Caucasian
East Asian
No
Yes
Other
Not stated
BMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/17
Page 7 of 12
(page number not for citation purposes)
instance may be complicated by the polymorphism being
associated with a number of different intermediate phe-
notypes that could have opposing effects on CHD and by
the fact that the principles of Mendelian randomisation
depend upon a very clear understanding of the functional
pathways from genotype, through intermediate pheno-
type, to disease outcome. Proving a negative using the
principles of Mendelian randomisation is difficult since it
requires the ability not simply to show a null genotype-
outcome association (as we suggest is the case here) but
the need to predict, from known effect sizes of the gene-
intermediate phenotype association and the intermediate
phenotype-outcome association, the size of effect that one
would expect for the genotype-outcome association [55].
Since there is no clear epidemiological evidence of the
effect sizes to make these predictions of the PON1 activ-
ity-CHD association (because of difficulties of reliably
estimating PON1 activity and oxidation of LDL in large
epidemiological studies) these calculations are not possi-
ble in this situation in the way that they have been shown
to be useful in other examples, most notably with the
fibrinogen-CHD association [55,56].
Knowledge of the link between PON1 activity and athero-
sclerosis comes largely form biological rather than epide-
miological studies. There is good evidence that
peroxidation of LDL lipids an important risk factor for
atherosclerosis and that HDL protects against atheroscle-
rosis at least in part through its antioxidative propreties
[4,57]. Whilst a number of HDL enzymes have antioxi-
dant properties purified PON1, in laboratory experi-
ments, has been found to be highly effective in preventing
lipid peroxidation of LDL and to be more effective than
other HDL enzymes [6-8,58,59]. Avian HDL has no PON1
and in studies that have isolated avian HDL and tested its
effects on human LDL it has been found to have no pro-
tective effect against lipid peroxidation [7]. Similarly in
studies of PON1 knockout mice their HDL fails to protect
against LDL oxidation [8]. Thus there is biological evi-
dence that HDL PON1 activity has important LDL antioxi-
dant effects. Since LDL oxidation is importantly linked to
atherosclerosis a genetic factor that had a direct effect on
PON1 activity should therefore be associated with CHD.
However, without epidemiological studies which provide
one with reliable estimates from which to clearly state the
magnitude of association one would expect in this path-
way we cannot rule out the possibility that an odds ratio
of 1.15 (the upper limit of the 95% confidence interval for
a dominant effect from the pooling of all studies with 500
or more cases) is consistent with the antioxidant activities
of PON1.
If the Q192R polymorphism has pleiotropic effects (the
potential for polymorphisms to have more than one spe-
cific phenotypic effect) with some, as yet unknown, phe-
notypic effect of the R allele that results in a decreased risk
of CHD then the overall effect of this polymorphism
could be null, but the antioxidant properties of PON1
activity could still be an important determinant of risk.
However, our own findings do not suggest that the PON1
R allele is associated with phenotypes that would reduce
CHD risk, and the unexpected association with increased
systolic blood pressure would increase CHD risk. Other
studies suggest that there are other effects of this pheno-
type that would actually increase rather than decrease
CHD risk including a possible association with diabetes
[14] and increased susceptibility to the effects of cigarette
smoking [60]. Thus although it is clear that there are a
number of different PON1 phenotypes and therefore pos-
sible that there is a phenotype which decreases CHD risk
and leads to the null or weak findings we present here. To
date the known PON1 phenotypes should in theory all
increase CHD risk.
Finally, it is possible that the PON1 Q192R polymor-
phism is not the true functional polymorphism for PON1
activity but is linkage disequilibrium with the functional
variant. Heterogeneity between studies could then result
from different ethnic groups being included in different
studies with different patterns of linkage disequilibrium
in these groups. However, though we found that ethnicity
was associated with heterogeneity it only explained a
small proportion of the differences between studies.
In conclusion, whilst our results suggest that there is no
robust evidence of an association between the PON1
Q192R polymorphism and CHD in Caucasian women
and men. This does not mean that PON1 enzyme activity
is not a determinant of atherosclerosis. Further, epidemi-
ological studies of the association between the genotype
and enzyme activity and between enzyme activity and
CHD are required to be able to use the results from this
meta-analysis and the principles of Mendelian randomi-
sation to determine whether there is a causal link between
the enzyme activity and CHD.
Study strengths and limitations
Ours is one of the few studies to examine this association
in a predominantly female population. Although our
results overall suggest that there is no difference in the
association between women and men the differences in
HDLc levels and CHD risk between the sexes warranted
specific examination of the association in women. Our
cohort study is moderately large with just under 500 clin-
ically diagnosed cases and the null result in this study sup-
ports the conclusion of a recent meta-analysis that this
polymorphism is not importantly associated with CHD
risk [13]. Genotypic data were available on 76% of the
total cohort but those without these data did not differ
with respect to age or CHD status from those with these
BMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/17
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data. Our cases were obtained from medical record. In the
case of MI these were validated against WHO criteria.
However, the MI cases accounted for only a small propor-
tion of all CHD cases. Whilst medical diagnoses of angina
are likely to be more accurate than self-reports it is possi-
ble that some of our cases are not truly CHD cases and as
a results our results are an underestimate of the true effect.
However, we found no heterogeneity between the pooled
effects of studies with harder outcomes (angiographic
assessments and well defined MI) and those with softer
measurements of CHD. There are two known polymor-
phisms in the PON1 gene and two in the PON2 gene all
of which could plausibly influence PON1 activity and
hence CHD risk [13]. We have genotypic data only on the
PON1 Q192R polymorphisms. However, this is the poly-
morphism which has been mostly studied in this area and
a recent meta-analysis found no associations between the
other three polymorphisms and CHD risk, with pooled
point estimates of per allele odds ratios between 1.00 and
1.04.
We attempted to obtain all published studies of the asso-
ciation for our meta-analysis and as well as updating a
recent meta-analysis with our own results we identified
three studies that had not been included in that analysis
[39,40,50]. Our analysis and the earlier publication found
small study bias consistent with publication bias. This is
demonstrated by one of the studies that we identified in
our meta-analysis, but that was not included in the previ-
ous meta-analysis, which was a small null study that was
difficult to obtain because of its publication in a difficult
to obtain Chinese journal.[40] Publication is probably a
greater problem for meta-analyses of genetic association
studies than for randomised controlled trials as, for the
latter, researchers and editors are much more aware of the
importance of publishing important null findings. A solu-
tion to this problem is setting up central web-sites for the
publication of all negative gene-disease association stud-
ies. We have initiated such a site (Archives of Genetic Epi-
demiological Analyses, http://
www.sgel.humgen.soton.ac.uk/agea/) and other laborato-
ries engaged also maintain web sites as a public domain
data repository (e.g. GeneCanvas, http://genecan
vas.idf.inserm.fr/). It seems likely that a synthesis of cen-
tralised and specific databases will evolve for complex
trait genetics, mirroring the locus specific and centralised
databases that currently exist for single gene disorders.
There is heterogeneity of study approaches, data analyses
and patterns of research, but the evolution of some com-
mon standards as these web-sites develop may help har-
monisation in addition to dealing with the important
issue of publication bias.
An important limitation of using Mendelian randomisa-
tion to provide trustworthy estimates of phenotype-dis-
ease associations is that as discussed above detailed
information on genotype function is required. With
advances in functional genomics, exciting new opportuni-
ties for using Mendelian randomisation to examine the
effects of environmental exposures on common diseases
that hitherto have proved difficult to study without con-
founding and bias are likely to arise [55].
Conclusions
Our findings suggest that there is no strong evidence that
the PON1 Q192R polymorphism is associated with CHD
risk in either Caucasian women or men. The role of the
HDLc PON1 enzyme in determining atherosclerotic risk is
unclear and requires further epidemiological study. The
results presented here may demonstrate the important pit-
falls of false positive gene-disease associations that can
occur due to failure to appreciate the play of chance and
publication bias.
Methods
British Women's Heart and Health Study
Full details of this study have been previously reported
[61,62]. Between 1999 and 2001 4,286 women aged 60 to
79 years, who were randomly selected from 23 British
towns were interviewed, examined and completed medi-
cal questionnaires [61]. These women have been fol-
lowed-up over a median of 3.5 years by flagging with the
NHS central register for mortality data, two yearly review
of their primary care medical records and a recently
mailed 3-year follow up health questionnaire sent to all
surviving participants between March and September
2003.
Methods used at baseline assessment have been previ-
ously described [61,62]. Briefly, blood samples were taken
after a minimum 6 hour fast. These samples were used for
assessment of insulin resistance (homeostasis model
assessment calculated from fasting insulin and glucose
levels) and lipids [62]. Blood pressure, height and weight
(used for calculating body mass index) and waist and hip
circumferences were measured [54]. In this study clinical
diagnostic criteria for CHD have been applied: a case of
myocardial infarction is defined as anyone with a diagno-
sis of infarction, based on world health organisation crite-
ria [63], in their medical records at baseline or during the
follow-up period and anyone who was assigned an under-
lying cause of death of CHD (ICD10 codes I20-I25, I51.6)
during the follow-up period; a case of angina is defined as
anyone with a clinical diagnosis of angina in their medical
records at baseline or during follow-up and who was not
included as an MI case; any CHD includes those defined
as having either and MI or history of angina.
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Determination of PON1 genotype
DNA was extracted by salting out procedure [64] from K-
EDTA whole bloods or red and white cell residues, which
had been stored at -80°C for 1 to 2 years. Quantitation
was by picoGreen assay and DNA concentrations were
equalised by dilutions with water. Long term stock DNA
aliquots were laid down and working 96-well plates of
DNA dilutions to 10 ng/µl prepared. Degenerate oligo
primer amplifications ('DOP-DNA') were made from
dilution plates in order to conserve stock DNA and 384-
well PCRs were performed from DOP-DNA representing
0.1 ng of original genomic DNA. The DOP protocol was a
modified version of the method used by Cheung and Nel-
son [65] designed to minimise loss of representation of
%GC-rich genomic regions. The PON1 Q192R genotype
was determined using fluorescence-labelled oligonuclo-
tide melting from matched or mismatched target, moni-
tored in an Idaho Technology (Salt Lake City, Utah, USA)
384-well Odyssey. Detection utilised reduction of
opposed G-base quenching of fluorescence during a ther-
mal ramp. Asymmetric PCR was performed on 2 µl of
dried DOP amplified template in 384-well white PCR
plates (Abgene®, Epson, Surrey, UK) on a MJ Research
PTC-225 DNA Engine Tetrad® (Genetic Research Instru-
mentation Ltd., Braintree, Essex, UK). Samples were
amplified with primers 5'-CTGTGGGACCTGAGCACTTT-
3' at 100 nM and 5'-GCCACCACTCGAACTTCACT-3' at
500 nM. A FITC-labelled probe (with 3' phosphate) 5'-
FITC-CCCTACTTACAATCCTGGGAG-PHOS-3' matching
the wild-type sequence (underlined) was included at 200
nM in the PCR for the Odyssey melting assay. 5 µl PCR
reaction mix also contained: 1x PCR buffer (Promega,
Southampton, UK), 200 µM dNTPs (Promega), 1.5 mM
MgCl2 (Promega) and 0.1 units of Taq DNA polymerase
(Promega). PCR cycling conditions were: 94°C for 2 min-
utes then 50 cycles of 94°C for 30 seconds, 60°C for 30
seconds and 72°C for 30 seconds, followed by 72°C for 2
minutes. Samples were overlaid with 5 µl Chill-Out™ wax
(Genetic Research Instrumentation) to prevent evapora-
tion during analysis. Following PCR amplification sam-
ples were melted from 45°C to 75°C in the 384-well
Odyssey. LightTyper software (Roche Diagnostics Ltd.)
was used to analyse the change in fluorescence during
melting, and to group melting profiles into genotype
groups. These were then manually verified using in-house
software.
Statistical analysis
Prevalences (for dichotomous variables) and means (for
continuous variables) are presented by genotype. ANOVA
was use for testing differences between genotypes for con-
tinuous variables and χ2 tests were used for testing differ-
ences between genotypes for dichotomous variables.
Logistic regression models were used for assessing the
association between genotype and CHD. Robust standard
errors, which take into account possible non-independ-
ence between women from the same town, were used in
all analyses to estimate confidence intervals and p-values.
All analyses were conducted using Stata version 8.
Study ethics
Local ethics committee approvals were obtained for the
British Women's Heart and Health Study. Participants
were asked for informed consent to review their medical
records and for permission to perform anonymised
genetic tests relating to cardiovascular disease on stored
blood. Eight women declined to give consent and have
not been included in this study.
Systematic review and meta-analysis
Studies assessing the association of the PON1 Q192R pol-
ymorphism with CHD were obtained through a search of
Medline (1966-January 2004) and Embase (1980-January
2004) electronic databases (using the following search
terms: paraoxonase, PON, PON1, Q192R, CHD, cardio-
vascular disease, atherosclerosis, myocardial infarction,
angina) and review of the bibliographies of retrieved arti-
cles. For each study odds ratios for a dominant effect
(comparing QR or RR genotype versus QQ genotype), a
recessive effect (comparing RR genotype to QR or QQ gen-
otype) and per (R) allele were abstracted from the publi-
cation or calculated from the data presented in the paper.
Odds ratios for each study were pooled using both ran-
dom and fixed effects methods [66]. Results from both
models are presented because whilst random effects mod-
els are used when heterogeneity between studies is appar-
ent (and this was likely among the studies we obtained),
they do not "fix" the problem. The random effects
method, compared to fixed effects, reduces the weight for
each individual study proportional to the difference in
effect size of an individual study from the pooled estimate
of effect for all other studies. As heterogeneity may be the
result of publication bias, a random effects model
combining several small positive studies (and an absence
of small negative studies due to publication bias) with a
large null study will tend to underweight the latter, result-
ing in exaggeration of the true effect. Funnel plots and
Egger and Begg's tests were used to assess whether smaller
studies reported greater associations than larger studies,
consistent with publication bias. [66] The effect of the
proportion of women in the study population (> 50%
compared to ≤ 50%), ethnicity of the study population
(Caucasian, East-Asian or Other), disease/risk status of
study participants (healthy versus high risk (diabetes,
familial hypercholesterolaemia, renal disease)), blinding
of the genotyping (blind to clinical status, not blind and
not stated in the publication) and diagnosis of CHD (ang-
iographic or clearly defined MI: two out of three of classi-
cal chest pain, cardiac enzyme change, ECG change versus
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other) was assessed using meta-regression analysis [66].
All analyses were undertaken using Stata version 8 [66].
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